Determination of ERCC2 Lys751G1n and GSTP1Ile105Va1 gene polymorphisms in colorectal cancer patients: Relationships with treatment outcome

Pharmacogenomics

Volumn 8, Issue 12, 2007, Pages 1693-1703

  Le Morvan, Valérie ^a   Smith, Denis ^b   Laurand, Armelle ^a   Brouste, Véronique ^c   Bellott, Ricardo ^a   Soubeyran, Isabelle ^c   Mathoulin Pelissier, Simone ^c   Robert, Jacques ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b HÔPITAL SAINT ANDRÉ   (France)

^c INSTITUT BERGONIÉ   (France)

Author keywords

Chemotherapy; Colorectal cancer; Excision repair cross complementing repair deficiency group 2 protein; Gene polymorphisms; Glutathione S transferase P1

Indexed keywords

CA 19-9 ANTIGEN; CAPECITABINE; DNA; FLUOROURACIL; FOLINIC ACID; GLUTAMINE; GLUTATHIONE TRANSFERASE P1; IRINOTECAN; ISOLEUCINE; LYSINE; OXALIPLATIN; RALTITREXED; VALINE; XERODERMA PIGMENTOSUM GROUP D PROTEIN; ERCC2 PROTEIN, HUMAN; GSTP1 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; DRUG EFFICACY; FEMALE; GENE FUNCTION; GENE IDENTIFICATION; GENETIC VARIABILITY; GENOTYPE; HEMOGLOBINOPATHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; UNIVARIATE ANALYSIS; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; MORTALITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; MALE; MIDDLE AGED; TREATMENT OUTCOME; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

EID: 37649009185     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.12.1693     Document Type: Article

References (31)

1. Hill C, Doyon F: The frequency of cancer in France in year 2000, and trends since 1950. Bull. Cancer 92, 7-11 (2005).
2. Boyle P, Ferlay J: Cancer incidence and mortality in Europe, 2004. Ann. Oncol. 16, 481-488 (2005).
3. Bentrem DJ, Dematteo RP, Blumgart LH: Surgical therapy for metastatic disease to the liver. Annu. Rev. Med. 56, 139-156 (2005).
4. Labianca R, Pessi MA, Zamparelli G: Treatment of colorectal cancer: current guidelines and future prospects for drug therapy. Drugs 53, 593-607 (1997).
5. de Gramont A, Figer A, Seymour M et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol. 18, 2938-2947 (2000).
6. Douillard JY, Cunningham D, Roth AD et al.: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 355, 1041-1047 (2000).
7. Cunningham D, Humblet Y, Siena S et al.: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351, 337-345 (2004).
8. Moses MA, Harper J, Fernandez CA: A role for antiangiogenic therapy in breast cancer. Curr. Oncol. Rep. 6, 42-48 (2004).
9. Taieb J, Artru P, Paye F et al.: Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a Phase II study. J. Clin. Oncol. 23, 502-509 (2005).
10. Salonga D, Danenberg KD, Johnson M et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6, 1322-1327 (2000).
11. Mariadason JM, Arango D, Shi Q et al.: Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 63, 8791-8812 (2003).
12. Arango D, Wilson AJ, Shi Q et al.: Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br. J. Cancer 91, 1931-1946 (2004).
13. van Kuilenburg AB, Meinsma R, Zonnenberg BA et al.: Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin. Cancer Res. 9, 4363-4367 (2003).
14. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159 (2004).
15. Stoehlmacher J, Park DJ, Zhang W et al.: Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J. Natl Cancer Inst. 94, 936-942 (2002).
16. Park DJ, Stoehlmacher J, Zhang W et al. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer. Cancer Res. 61, 8654-8658 (2001).
17. Park JY, Lee SY, Jeon HS, Tsao-Wei DD, Groshen S, Lenz HJ: Lys751 G1n polymorphism in the DNA repair gene XPD and risk of primary lung cancer. Lung Cancer 36, 15-16 (2002).
18. Harries LW, Stubbins MJ, Forman D, Howard GC, Wolf CR: Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer. Carcinogenesis 18, 641-644 (1997).
19. Moreno V, Gemignani F, Landi S et al.: Polymorphisms in genes of nucleotide and base excision repair: risk and prognosis of colorectal cancer. Clin. Cancer Res. 12, 2101-2108 (2006).
20. Benhamou S, Sarasin A: ERCC2/XPD gene polymorphisms and lung cancer: a HuGE review. Am. J. Epidemiol. 161, 1-14 (2005).
21. Spitz MR, Wu X, Wang Y et al.: Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res. 61, 1354-1357 (2001).
22. Qiao Y, Spitz MR, Guo Z et al.: Rapid assessment of repair of ultraviolet DNA damage with a modified host-cell reactivation assay using a luciferase reporter gene and correlation with polymorphisms of DNA repair genes in normal human lymphocytes. Mutat. Res. 509, 165-174 (2002).
23. Tang D, Cho S, Rundle A et al.: Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res. Treat. 75, 159-166 (2002).
24. Matullo G, Peluso M, Polidoro S et al. Combination of DNA repair gene single nucteotide polymorphisms and increased levels of DNA adducts in a population-based study. Cancer Epidemiol. Biomarkers Prev. 12, 674-677 (2003).
25. Lunn RM, Helzlsouer KJ, Parshad R et al.: XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21, 551-555 (2000).
26. Laine JP, Mocquet V, Bonfanti M, Braun C, Egly JM, Brousset P: Common XPD (ERCC2) polymorphisms have no measurable effect on nucleotide excision repair and basal transcription. DNA Repair 6, 1264-1270 (2007).
27. Xu Z, Chen ZP, Malapetsa A et al. DNA repair protein levels vis-à-vis anticancer drug resistance in the human tumor cell lines of the National Cancer Institute drug screening program. Anticancer Drugs 13, 511-519 (2002).
28. Hartmann C, Xu X, Bartels G et al.: PDGFR-α in 1p/19q LOH oligodendrogliomas. Int. J. Cancer 112, 1081-1082 (2004).
29. Ban N, Takahashi Y, Takayama T et al. Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res. 56, 3577-3582 (1996).
30. Nishimura T, Newkirk K, Sessions RB et al.: Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin. Cancer Res. 2, 1859-1865 (1996).
31. Srivastava SK, Singhal SS, Hu X, Awasthi YC, Zimniak P, Singh SV: Differential catalytic efficiency of allelic variants of human glutathione S-transferase π in catalyzing the glutathione conjugation of thiotepa. Arch. Biochem. Biophys. 366, 89-94 (1999).